^
Association details:
| Biomarker: | BRCA1 mutation + HER-2 negative |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Zejula (niraparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Neoadjuvant niraparib in patients with HER2-negative, BRCA mutated resectable breast cancer
Published date:
03/12/2021
Excerpt:
Neoadjuvant niraparib exhibited antitumor activity, no new safety signals, and high intratumoral concentration in patients with HER2-negative, BRCA-mutated BC.
